Health insurance is big business, according to revenue reports from major players in the space. In fact, the five largest conglomerates in healthcare and pharmaceuticals are on track to outpace revenues of the five preeminent technology companies, according to Axios.

Medicare and Medicaid prices have grown at a slower pace than the private market, according to an analysis from the Urban Institute.

Oregon lawmakers are “taking another pass” at universal healthcare for the residents of state, according to a new report by The Register Guard. If SB 770 is passed, it will create a committee that would “design, implement and run a state health insurance plan.” 

Johnson & Johnson (J&J) will provide the list price of its prescription drugs in television advertisements starting in late March. The company will be the first manufacturer to take such a step, according to The New York Times.

As the rising drug price issue has taken hold of the healthcare debate in the U.S., Democrats in Congress have introduced a bill that would allow Medicare to negotiate drug prices. 

The price for a drug that treats Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder that impacts strength and impairs walking, went from cost-free to the price of a house—$375,000 to be exact. 

Approximately two-thirds of U.S.-based hospitals and acute-care facility leaders believe diagnosis-related group (DRG) optimization is still a problem that needs to be solved in revenue cycle management, according to a recent survey conducted by BESLER and HIMSS Media.

Families with subsidized health insurance through the Affordable Care Act (ACA) may experience indirect financial benefits that go beyond health costs—to housing, according to new research published in the Journal of Public Economics.